Insmed (INSM) Net Income towards Common Stockholders Growth (3y) (2013 - 2026)
Powered by 
Analysis
Insmed (INSM) Net Income towards Common Stockholders Growth (3y) (2013 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 208.48 Bn | 194.49 Bn | 7.24 Bn | 19.87% |
| 2 | Gilead Sciences | 186.29 Bn | 183.02 Bn | 6.22 Bn | -129.59% |
| 3 | Vertex Pharmaceuticals | 128.79 Bn | 120.93 Bn | 2.84 Bn | 6.30% |
| 4 | Regeneron Pharmaceuticals | 80.66 Bn | 72.67 Bn | 3.93 Bn | 10.23% |
| 5 | Moderna | 61.46 Bn | 56.32 Bn | 52.00 Mn | 17.25% |
| 6 | Argenx Se | 61.28 Bn | 56.10 Bn | 1.37 Bn | 91.31% |
| 7 | Alnylam Pharmaceuticals | 32.04 Bn | 28.73 Bn | 992.69 Mn | 37.44% |
| 8 | Biogen | 31.84 Bn | 30.56 Bn | 1.96 Bn | -45.23% |
| 9 | Roivant Sciences | 28.74 Bn | 29.43 Bn | 1.16 Mn | - |
| 10 | Insmed | 26.19 Bn | 25.03 Bn | 358.27 Mn | 62.15% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 62.15% |
| Mar 31, 2026 | -0.79% |
| Dec 31, 2025 | -27.06% |
| Sep 30, 2025 | -41.31% |
| Jun 30, 2025 | -49.83% |
| Mar 31, 2025 | -39.45% |
| Dec 31, 2024 | -27.75% |
| Sep 30, 2024 | -25.07% |
| Jun 30, 2024 | -36.84% |
| Mar 31, 2024 | -19.68% |
| Dec 31, 2023 | -22.10% |
| Sep 30, 2023 | -35.66% |
| Jun 30, 2023 | -58.18% |
| Mar 31, 2023 | -34.02% |
| Dec 31, 2022 | -44.57% |
| Sep 30, 2022 | -29.29% |
| Jun 30, 2022 | -12.87% |
| Mar 31, 2022 | -8.46% |
| Dec 31, 2021 | -7.25% |
| Sep 30, 2021 | -8.71% |